Benzene Ring Nonionically Bonded Patents (Class 514/567)
  • Patent number: 10377698
    Abstract: Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. esters, ethers, amides), processes for their preparation and their application in the manufacture of pharmaceutical products.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 13, 2019
    Assignee: University of Innsbruck
    Inventors: Helmut Schmidhammer, Mariana Spetea, Elena Guerrieri
  • Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10258585
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 16, 2019
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Patent number: 10092549
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10028927
    Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: July 24, 2018
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventor: Adrian Davis
  • Patent number: 9782376
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: October 10, 2017
    Assignee: Fresenius Kabi USA LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • Patent number: 9707197
    Abstract: The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 18, 2017
    Assignee: Multimode Medical Inc.
    Inventor: Patrick Musitano
  • Patent number: 9682923
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: June 20, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9636316
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: May 2, 2017
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 9622996
    Abstract: A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 18, 2017
    Inventors: Shuguang Lin, Meng Zheng
  • Patent number: 9610269
    Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: April 4, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala
  • Patent number: 9579385
    Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: February 28, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
  • Patent number: 9561277
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 7, 2017
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Patent number: 9555025
    Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: January 31, 2017
    Assignees: Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corporation
    Inventors: Tomoki Sakaguchi, Hidetoshi Emi
  • Patent number: 9504650
    Abstract: A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red color is reduced significantly, making the pharmaceutical composition acceptable for intranasal use.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: November 29, 2016
    Inventor: Klaas Alouis Riepma
  • Patent number: 9427446
    Abstract: The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 30, 2016
    Assignee: EPIFARMA S.R.L.
    Inventors: Giuseppe Irianni, Cristina Macelloni, Luca Teseschi
  • Patent number: 9381255
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: July 5, 2016
    Assignee: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC
    Inventors: Leo Rubin, Shaker Mousa
  • Patent number: 9371297
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: June 21, 2016
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
  • Patent number: 9364453
    Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: June 14, 2016
    Assignee: Lundbeck NA Ltd.
    Inventors: Saburo Sakoda, Kei Fukada
  • Patent number: 9271961
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Patent number: 9238016
    Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 19, 2016
    Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
    Inventors: Kyeong Kyu Kim, Sung Wook Kang
  • Patent number: 9180108
    Abstract: Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 10, 2015
    Assignee: Medtronic, Inc.
    Inventors: Michael C. Schmitz, Corinne Dominguez, Thomas E. Keene, Deanna S. Lane, Lanchi T. Le, Jianwei Li, Ngoc T. Lu, Carmen E. Snaza
  • Patent number: 9168239
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Patent number: 9168238
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 8, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Patent number: 9101645
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: August 11, 2015
    Assignee: Genentech, Inc.
    Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
  • Patent number: 9061968
    Abstract: Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: June 23, 2015
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Saroop Singh Matharu, Gurijala Venu Reddy, James J. Mencel, Xiaoyong Sun
  • Patent number: 9056814
    Abstract: The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: June 16, 2015
    Assignee: LEO PHARMA A/S
    Inventors: Soren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 9050307
    Abstract: Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3?,5?-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 9, 2015
    Assignee: EMP Pharma GmbH
    Inventors: Yannis Psarrakis, Konstantinos I. Lioumis
  • Publication number: 20150148355
    Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventor: John Olin Trimble
  • Publication number: 20150148420
    Abstract: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from nighttime reflux or gastroesophageal reflux disease (GERD) by administering a pharmaceutically effective amount of baclofen.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 28, 2015
    Inventor: William C. Orr
  • Publication number: 20150147282
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20150148325
    Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 28, 2015
    Inventors: Shimon Amselem, Michael Naveh
  • Publication number: 20150147281
    Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 28, 2015
    Inventors: Patricia A. Denny, Paul C. Denny, Mahvash Navazesh
  • Publication number: 20150147385
    Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Lawrence Helson
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Patent number: 9040582
    Abstract: A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: May 26, 2015
    Inventor: Raymond M. Keller
  • Patent number: 9040578
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9040553
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 26, 2015
    Assignee: CELL VIABLE CORPORATION
    Inventors: Iraj Lalezari, Jill Fabricant
  • Patent number: 9040577
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Publication number: 20150141389
    Abstract: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active.
    Type: Application
    Filed: March 11, 2013
    Publication date: May 21, 2015
    Inventors: Hyder Aliyar, Robert Huber, Gary Loubert, Gerald Schalau
  • Publication number: 20150141515
    Abstract: The invention relates generally to non-steroidal anti-inflammatory drugs (NSAIDs) and anesthetics, and more particularly, to NSAID and anesthetic compositions, methods of preparing/producing the compositions and methods of delivering, distributing and administering the compositions to patients.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Applicant: FIRSTLINE MEDS, INC.
    Inventors: JAY A. STOLTENBERG, SHANE HAINES
  • Publication number: 20150132380
    Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 14, 2015
    Applicant: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
  • Publication number: 20150133414
    Abstract: It was determined whether SNPs in SLC4A5 are associated with salt sensitivity of blood pressure (BP). Subjects consumed an isocaloric constant diet with a randomized order of 7 days low Na+ (10 mmol/d) and 7 days high Na+ (300 mmol/d) intake. Salt sensitivity was defined as a ?7 mm Hg increase in mean arterial pressure (MAP). 35 polymorphisms in 17 candidate genes were assayed. Association analyses with salt sensitivity revealed three variants that associated with salt sensitivity, two in SLC4A5 (rs7571842, rs10177833; P<0.001), and one in GRK4 (rs1801058; P=0.020). Paradoxical changes in blood pressure in response to changes in salt intake were also found associated with a SNP for DRD2 (rs6276). In conclusion, SLC4A5 variants are strongly associated with salt sensitivity of BP in Caucasian and a DRD2 SNP is a marker for paradoxical response to salt intake.
    Type: Application
    Filed: April 22, 2013
    Publication date: May 14, 2015
    Applicant: University of Virginia Patent Foundation
    Inventors: Robin A. Felder, Robert M. Carey, John E. Jones, Pedro A. Jose, Scott M. Williams
  • Publication number: 20150133557
    Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that possess a therapeutically effective amount of a levothyroxine sodium; an antioxidant in an amount sufficient to inhibit oxidation of the levothyroxine sodium in the unit dosage form; an amount of a calcium phosphate sufficient to facilitate a processing of the levothyroxine into the unit dosage form, and two or more excipients selected from the group consisting of a filler, a binder, a glidant, a lubricant, a disintegrant, and a surfactant. In such embodiments, the compositions are free of added alditol, added monosaccharide, added disaccharide, and added oligosaccharide and are storage stable.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 14, 2015
    Inventors: Nilesh Parikh, William Hite
  • Publication number: 20150132396
    Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: SIGMOID PHARMA LIMITED
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
  • Publication number: 20150126481
    Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150126606
    Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Ed Kisak, Jagat Singh
  • Publication number: 20150126607
    Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Ed Kisak, Jagat Singh
  • Publication number: 20150126605
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: Gregory T. Went, Timothy J. Fultz